Discussion
Gilead Sciences and Lakefront Biotherapeutics have acquired Ouro Medicines and its investigational therapy, gamgertamig, for cold agglutinin disease (CAD) and other forms of autoimmune hemolytic anemia (AIHA). Gamgertamig is also being developed as a treatment for several other autoimmune diseases. Under the deal, valued at up to $2.175 billion,…